Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Zentalis Pharmaceuticals

26/03/2025 20:53

Zentalis Pharmaceuticals Inc ZNTL.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -93 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -99 cents to -47 cents per share.

Revenue was $26.87 million​; analysts expected zero.

Zentalis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 67 cents​.

The company reported a quarterly loss of $47.47 million.

Zentalis Pharmaceuticals Inc shares had fallen by 38.3% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 10.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $7.00

This summary was machine generated from LSEG data March 26 at 08:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.71
-0.62
Beat
Sep. 30 2024
-0.91
-0.56
Beat
Jun. 30 2024
-0.84
-1.24
Missed
Mar. 31 2024
-0.77
0.14
Beat